Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Is Banco Santander (SAN) Stock Undervalued Right Now?
11:25am, Thursday, 09'th Mar 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Communiqué de presse: Dupixent® (dupilumab) : la FDA accepte d’examiner la demande d'indication pour le traitement de l’urticaire chronique spontanée de l’adulte et de l’adolescent à partir de 12 ans
06:00am, Tuesday, 07'th Mar 2023 GlobeNewswire Inc.
Dupixent® (dupilumab) : la FDA accepte d’examiner la demande d'indication pour le traitement de l’urticaire chronique spontanée de l’adulte et de l’adolescent à partir de 12 ans
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
06:00am, Tuesday, 07'th Mar 2023 GlobeNewswire Inc.
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
07:00am, Thursday, 02'nd Mar 2023 GlobeNewswire Inc.
Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO™ to redefine expectations for treatment of children <12 years of age with hemophilia A
L’étude XTEND-Kids de phase III, désormais clôturée, a démontré qu’ ALTUVIIIO™ a le potentiel de redéfinir les attentes relatives au traitement des enfants de moins de 12 ans atteints d
Is Hartford Multifactor Developed Markets (ex-US) ETF (RODM) a Strong ETF Right Now?
11:20am, Wednesday, 01'st Mar 2023 Zacks Investment Research
Smart Beta ETF report for RODM
Santander to raise payout policy to 50% from 40% in next three years
07:59am, Tuesday, 28'th Feb 2023 MarketWatch
Ahead of an investor day in London, the Spanish bank said it aims to add 40 million customers to reach 200m by 2025, boosting revenue growth by 7%-8% a year.
Santander intends to return half of profits to shareholders as details plan for growth
06:42am, Tuesday, 28'th Feb 2023
Banco Santander (LSE:BNC) SA said on Tuesday it intends to increase pay-outs to shareholders to 50% of profits from 40% as the lender laid out plans for higher profitability and growth alongside full-
Santander to raise payout policy to 50% from 40% in next three years
02:59am, Tuesday, 28'th Feb 2023
Banco Santander SA SAN, +2.08% said Tuesday that it would boost the proportion of profit distributed to shareholders to 50% in the next three years from 40% in 2022 through both cash dividends and sha
Stocks To Watch: Tesla, Rivian, Chevron, And Goldman Sachs Could See Jolts
03:00pm, Saturday, 25'th Feb 2023 Seeking Alpha
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
04:16pm, Friday, 24'th Feb 2023 GlobeNewswire Inc.
La présentation de nouvelles données de phase III au WORLDSymposium™ conforte le positionnement de Nexviazyme® (avalglucosidase alpha) comme nouveau médicament de référence pour toutes les per
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
03:31pm, Friday, 24'th Feb 2023 GlobeNewswire Inc.
New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
Sanofi gets FDA approval for hemophilia drug
06:55am, Friday, 24'th Feb 2023 MarketWatch
The French pharmaceutical company FR:SAN said this is the first approval of the drug, previously referred to as efanesoctocog alfa, and that regulatory submission in the European Union is expected in
